Company ·
The United Laboratories International holds a peptide molecule tracked on the Peptide Exchange board.
The United Laboratories International has 1 molecule on the board and 1 news move logged. Each card shows the molecule's class, mechanism and current stage; open it for the full stage history.
Holdings
Incretins
Single peptide agonist of the GLP-1, GIP and glucagon receptors
A once weekly triple agonist from The United Laboratories, licensed to Novo Nordisk outside Greater China in March 2025. Phase 3 diabetes trials began in China in September 2026.
Log
The peer reviewed paper confirms the March topline for the GLP 1, GIP and glucagon triple agonist: up to 2.16 points off HbA1c and up to 9.8 percent off body weight at 24 weeks. Two phase 3 diabetes trials in China are already dosing.
Holds P3